OC METRO CALENDAR

  • July 2014
    SuMoTuWeThFrSa
    293012345
    6789101112
    13141516171819
    20212223242526
    272829303112
    3456789
Add an event

PHARMACEUTICALS
Untitled Page Published: May 18, 2009 10:40 AM



AMDL, continued ...

This will include launching a marketing strategy and program execution to drive product awareness and sales. GenWay Biotech will bear all responsibility for these activities. The potential value of these agreements is at least $15.8 million over a 5-year period.

"The US and Canada are major world markets for in vitro diagnostic products," says Douglas MacLellan, chairman and CEO of AMDL. "We believe that GenWay Biotech is well positioned to drive market adoption with CLIA laboratories in these significant markets.

"This is a substantial moment in the history of AMDL's Tustin-based operations – not only does this agreement validate DR-70 as a viable cancer diagnostic product, it puts AMDL's diagnostic division on a solid path to profitability," continues MacLellan

<< PREVIOUS PAGE

Related headlines
Costa Mesa’s Oxygen Biotherapeutics inks deal with U.S. Navy
UC Irvine banks $45 million for infectious disease research
NIH: Masimo's SpCo may gauge asthma severity in kids
May is Huntington's Disease Awareness month
UC Irvine Medical Center lands stroke therapy center designation